Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Deferred Revenue (2016 - 2025)

Ascendis Pharma A (ASND) has disclosed Current Deferred Revenue for 8 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 475.39% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Dec 2025, up 475.39% year-over-year, with the annual reading at $5.8 million for FY2025, 475.39% up from the prior year.
  • Current Deferred Revenue hit $5.8 million in Q4 2025 for Ascendis Pharma A, up from $1.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $5.8 million in Q4 2025 to a low of $1.0 million in Q4 2024.
  • Historically, Current Deferred Revenue has averaged $2.8 million across 4 years, with a median of $2.1 million in 2021.
  • Biggest five-year swings in Current Deferred Revenue: soared 587.49% in 2021 and later fell 21.49% in 2024.
  • Year by year, Current Deferred Revenue stood at $3.0 million in 2021, then plummeted by 57.19% to $1.3 million in 2023, then fell by 21.49% to $1.0 million in 2024, then soared by 475.39% to $5.8 million in 2025.
  • Business Quant data shows Current Deferred Revenue for ASND at $5.8 million in Q4 2025, $1.0 million in Q4 2024, and $1.3 million in Q4 2023.